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Although treatment for advanced epithelial ovarian cancer has improved over recent years with the introduction of taxane–platinum
chemotherapy, the majority of patients will relapse, and in most the disease remains incurable. A thorough understanding of drug
resistance mechanisms is needed, as this remains the largest obstacle in treating patients with recurrent disease. Multidrug resistance
proteins, mismatch repair processes and alterations in the p53 pathway are examples of properties within tumour cells that may lead
to drug resistance. Novel agents designed to circumvent these mechanisms (e.g. PSC 833, ONYX-015 and ADP53) are currently
being investigated for ovarian cancer patients. Further improvements may result from the optimisation of existing first-line regimens
with more creative schedules, perhaps involving sequential or intraperitoneal administration of existing drugs, and the incorporation
of newer noncross-resistant drugs.
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Treatment for epithelial ovarian cancer has improved over the past
20 years with the introduction of the platinums and, more recently,
taxane-based chemotherapy. The results of randomised-controlled
trials have established paclitaxel in combination with a platinum
agent as a standard initial chemotherapy for advanced ovarian
cancer patients (McGuire et al, 1996; Piccart et al, 2000; du Bois
et al, 2003; Ozols et al, 2003). Recent studies have suggested that
docetaxel–carboplatin is as effective as paclitaxel–carboplatin
chemotherapy (Vasey, 2001; 2002).
Despite these treatment advances, most patients will relapse
after achieving complete clinical response, and in the majority of
these patients the disease is incurable (Lister-Sharp et al, 2000). As
a result, the treatment of recurrent disease is an important aspect
in the overall management of patients with epithelial ovarian
cancer. A thorough understanding of drug resistance mechanisms
is needed, as this remains the largest obstacle in treating patients
with recurrent disease. Alterations to current taxane–platinum
therapy such as the incorporation of newer noncross-resistant
drugs, sequential therapy and intraperitoneal (i.p.) administration
may help improve survival duration. This review examines some of
the major mechanisms of resistance of tumours to anticancer drugs
with particular reference to advanced epithelial ovarian cancer, and
the means by which both clinical and laboratory researchers are
seeking to circumvent these mechanisms in patients.
CELLULAR MECHANISMS OF DRUG RESISTANCE
A wide range of metabolic or structural properties within tumour
cells may lead to drug resistance. The identified mechanisms
(Goldenberg, 1998) include:
  decreased drug uptake,
  increased drug efflux,
  increased repair of DNA damage induced by chemotherapy and
  reduced ability to undergo apoptosis.
In addition, because cancer cells are heterogeneous, more than
one mechanism of drug resistance may be present in any particular
case.
As shown in Table 1, a number of specific factors have been
identified as causes of taxane and/or platinum resistance in vitro,
although the clinical relevance of the majority of these requires
clarification (Kaye, 2000). Translational studies involving the
prospective collection of tumour samples from the same patient
before treatment and on clinical relapse are likely to be integral in
ascertaining the clinical relevance of resistance. Circulating blood
has been shown to contain free tumour DNA and tumour cells in
most cancer patients (Leon et al, 1997). Sequential sampling of
blood for molecular changes in blood tumour DNA may be a
convenient means of monitoring the in vivo development of
tumour resistance mechanisms.
Classical multidrug resistance
Many drugs are substrates for membrane-based proteins (from the
ATP-binding cassette family) that actively pump drugs out of cells.
The expression of these proteins can cause multidrug resistance
(MDR) towards numerous anticancer drugs, including the taxanes
(Goldenberg, 1998). Two important MDR-associated proteins are
P-glycoprotein and MDR-associated protein (MRP). One study
investigated the role of MDR markers in predicting chemotherapy
response in ovarian cancer patients by analysing samples taken
from 58 patients at initial surgery (Yokoyama et al, 1999). The
5-year disease-free survival rate was 26.0% for patients with
MRP-positive tumours and 72.5% for those with MRP-negative
tumours. The prognosis for patients with MRP-positive tumours
was significantly poorer (Po0.05), which suggests that MRP is a *Correspondence: Dr PA Vasey; E-mail: P.vasey@beatson.gla.ac.uk
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(Yokoyama et al, 1999).
Valspodar (PSC 833) is an MDR modulator — designed to
reverse drug resistance-mediated through P-glycoprotein — that is
currently undergoing clinical investigation. In a Phase I/II study,
59 patients with recurrent ovarian cancer who had failed prior
platinum- and anthracycline-based chemotherapy were treated
with valspodar (2, 4 or 10mgkg
 1day
 1) over 3 days, followed by
doxorubicin (20–50mgm
 2) and cisplatin (50mgm
 2) on day 3
(Baekelandt et al, 2001). The addition of valspodar did not worsen
cisplatin-related toxicity, and, of the 33 patients treated at the
maximum-tolerated dose, one patient had a complete response
(3%) and four (12%) had a partial response. In another study, 60
patients with refractory ovarian cancer were treated with valspodar
(5mgkg
 1) four times daily for 12 doses and paclitaxel
(70mgm
 2) on day 2, 2h after the fifth or sixth dose of valspodar
(Fracasso et al, 2001). The combination had limited activity
(median progression-free survival (PFS) 1.5 months), although the
authors suggested that patients with paclitaxel- and platinum-
resistant tumours may not be an ideal trial population. It is
hypothesised that initial treatment with valspodar in combination
with taxane–platinum chemotherapy may suppress the emergence
of resistant tumour cells. The first results of a large, multicentre,
randomised trial of carboplatin AUC 6 plus paclitaxel 175mgm
 2
vs carboplatin AUC 6 plus paclitaxel 80mgm
 2 plus PSC 833 on
days 0–3 of each cycle were presented at ASCO in 2002 (Joly et al,
2002). The dose of paclitaxel was reduced due to the increased
toxicity observed in the previous studies when combined with PSC
833. Despite this, patients receiving chemotherapy plus PSC 833
demonstrated more myelotoxicity and emesis, in addition to
ataxia — a toxicity largely unexplained, but again seen in Phase II
studies. The chemotherapy-only arm demonstrated more neuro-
pathy. However, there were no significant differences in the
median time to progression (13.2 vs 13.5 months, HR.960). The
overall survival was too premature, but this analysis suggests
that MDR modulation in this manner may be of limited clinical
relevance in ovarian cancer. It has been suggested that multiple
mechanisms may need to be targeted to have any clinically
important impact on outcome.
Mismatch repair
Mismatch repair (MMR) proteins such as hMSH2 and hMLH1
recognise and repair damaged or mismatched DNA. Defects in the
MMR pathway are an example of molecular events that may be
associated with ovarian cancer resistance. Experimental data
indicate that deficiencies in hMLH1 result in ‘replicative bypass’
following exposure to cytotoxic agents, by which DNA damage is not
recognised and tumour cells continue to divide (Brown et al, 1997).
The clinical relevance of MMR is currently being assessed via blood
tumour DNA in a large-scale Scottish Gynaecological Trials Group
study (SCOTROC 1). Blood samples from nearly 1000 patients (all
prior to chemotherapy and as they relapse) are being collected and
will be analysed for the presence of microsatellite instability (a DNA
change indicative of defects in MMR). Approximately 70% of the
first 150 patients analysed have abnormalities consistent with the
presence of tumour DNA and 28% have microsatellite instability
(Kaye, 2001). The analysis of samples collected after relapse is
likely to be of key relevance in gauging the clinical importance of
MMR in ovarian cancer resistance.
p53 protein
The p53 protein is involved in controlling the progression of cells
through the cell cycle and in mediating cellular responses to DNA
damage through modulation of cell cycle regulation, DNA repair
and activation of pathways leading to apoptosis (Benchimol and
Minden, 1998). Mutations in the p53 gene are associated with a
lack of response to high-dose cisplatin therapy in ovarian cancer
patients (Righetti et al, 1996). Interestingly, preclinical investiga-
tions show that p53 mutations and the acquisition of cisplatin
resistance are associated with increased sensitivity to taxanes in
ovarian carcinoma cells (Cassinelli et al, 2001). The efficacy of the
taxanes against mutant p53 ovarian cancer has been demonstrated
in the clinical setting (Lavarino et al, 2000). Of 48 previously
untreated patients with advanced disease, 34 (71%) responded to
paclitaxel-based chemotherapy. Among the patients with mutant
p53, 86% responded to therapy while only 47% of patients with
wild-type p53 responded to the same therapy. Although other
factors may be confounding, it may be possible to harness this
increased sensitivity by targeting patients with platinum-resistant,
p53-negative tumours for taxane therapy. Further studies are
required in this area.
Genetic therapies are being explored as alternative approaches
to circumventing p53-induced resistance in ovarian cancer (Wolf
et al, 2000; Kigawa et al, 2001; Vasey et al, 2002). One such
approach is the use of the adenovirus ONYX-015, attenuated so
that it replicates in cells with absent or nonfunctional p53. This
leads to virus spread and subsequent cytolysis of tumour cell
populations. In a Phase I trial, 16 patients with recurrent ovarian
cancer received i.p. ONYX-015. The maximum-tolerated dose was
not reached at 1 10
11 plaque-forming units; at this dose level
patients selected for nonbulky i.p. disease did not experience
significant dose-limiting toxicities. The evidence of virus replica-
tion was seen in the peritoneal fluid in one patient for up to 17
days (Vasey et al, 2002); this study therefore described the first
clinical experience of any replication-competent/selective virus in
cancer patients. Wolf et al (2000) have investigated a complemen-
tary approach in which wild-type p53 is reintroduced into tumour
cells using adenovirus ADP53 in an attempt to restore chemo-
sensitivity and promote apoptosis. Preliminary results from the
Phase I study in 14 evaluable patients demonstrate that i.p. ADP53
is feasible and well tolerated (Wolf et al, 2000). A large-scale,
randomised trial is underway to assess the potential of this
approach in combination with platinum-based chemotherapy.
STRATEGIES FOR MODULATING DRUG RESISTANCE
Combination therapy with noncross-resistant agents
When ovarian cancer recurs, the goal of therapy shifts from cure to
palliation. The treatment of recurrent ovarian cancer involves the
use of second- or third-line drugs chosen for their lack of
crossresistance with the primary agents employed. In contrast to
the situation in previously untreated patients for whom prospec-
tive randomised trials have established the current taxane–
platinum standards, there have been few randomised trials in
patients with recurrent disease that demonstrate a survival
advantage for one particular drug or regimen (Ozols, 2002).
However, 2003 saw the results of the first adequately powered
clinical trial in recurrent disease that demonstrated a survival
advantage for combination chemotherapy over single-agent plati-
num (Parmar et al, 2003). Perhaps, more significant was the fact
Table 1 Mechanisms of in vitro drug resistance
Taxanes Platinum agents
m Export from cells by P-glycoprotein k Net uptake into cells
Mutations of tubulin k Mismatch repair
k Apoptosis k Apoptosis
Alterations in cell signalling (e.g. raf-1/bcl-2) Alterations in activation and
DNA repair
Mutations in p53
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toxicity, quality of life) from the paclitaxel carboplatin combina-
tion over platinum monotherapy in relapsed disease.
A series of single agents has been shown to have clinical activity
in recurrent ovarian cancer; the most recent examples of these
include topotecan, irinotecan (CPT-11), liposomal doxorubicin,
gemcitabine and vinorelbine (Takeuchi et al, 1991; Burger et al,
1999; Ozols, 2002). Most notably, it has also been demonstrated
that retreatment with either a platinum or a taxane is associated
with significant clinical activity in patients with recurrent disease
(Gore et al, 1990; Markman et al, 1991; Thigpen et al, 1994; Abu-
Rustum et al, 1997). For example, single-agent docetaxel is an
active second-line agent in patients refractory to both paclitaxel-
and platinum-based regimens (Kavanagh et al, 1996; Katsumata
et al, 2000; Verschraegen et al, 2000), which suggests that
resistance to a specific agent does not necessarily mean that the
tumour will not respond to other agents in the same class.
The treatment-free interval (TFI), defined as the period of time
between the end of first-line chemotherapy and the start of second-
line therapy, may assist in deciding on a second-line therapy.
Markman et al (1991) have shown that a TFI of between 6 and 24
months predicts for a response rate of 30% to second-line
platinum, while a TFI 424 months predicts for a response
rate of approximately 60%. It has since been suggested that it
may be possible to increase the platinum-free interval by using an
alternative agent first, thereby saving platinum for later (Bookman,
1999; Cannistra, 2002). The taxanes, topotecan and liposomal
doxorubicin have potential as alternative agents in this setting.
In support of this, a subset of platinum-resistant patients were
converted to a platinum-sensitive state through the interval use
of paclitaxel in a small trial (n¼33), presumably by allowing
the emergence of platinum-sensitive tumour cells (Kavanagh et al,
1995). Likewise, a similar study demonstrated a response rate
of 26% to platinum rechallenge in patients considered platinum
resistant by treatment with nonplatinum agents in the intervening
period (Spriggs et al, 2002). Laboratory data have hinted that
the underlying mechanism for this may be the downregulation
with time — in the absence of platinum — of excision repair
enzymes, known to be overexpressed in resistant disease
(Dabholkar et al, 1992; Yu et al, 2000). On the basis of these
observations, the concept of prolonging the platinum-free interval
is a strategy that some physicians have already adopted in clinical
practice (Cannistra, 2002). However, such a strategy requires
randomised trial data, and two studies are addressing this —
Gynaecologic Oncology Group (GOG) trial 202 (this is primarily
directed at investigating the role of secondary cytoreduction) and
the planned Optimum Sequence of Chemotherapy At Relapse,
OSCAR trial in the UK.
Sequential therapy
Sequential therapy is an approach designed to avoid the develop-
ment of drug resistance. One agent is used initially and then
treatment is switched in order to — in principle — eliminate cells
that may have developed resistance to continued use of the initial
therapy (Kaye, 2000). Potential advantages are that full doses of the
most potent agent can be administered initially and differential
sensitivities of tumour cells to certain agents can be exploited.
Such regimens may offer improved tolerability and reduced risk of
negative interactions between agents. This approach has proved
successful in breast cancer for a number of regimens, including
sequential docetaxel followed by doxorubicin and cyclophosphamide
(Khayat et al, 2001), and sequential docetaxel and 5-fluorouracil–
epirubicin–cyclophosphamide (Spielmann et al, 2002).
The numerous active drug classes in ovarian cancer mean that
many sequential chemotherapy regimens are possible. Although
there is a current lack of completed trials using a truly sequential
approach, one GOG trial 132 does hint at the value of sequential
taxane therapy in ovarian cancer (Muggia et al, 2000). This three-
arm study compared paclitaxel 135mgm
 2 over 24h plus cisplatin
75mgm
 2 with cisplatin 100mgm
 2 or paclitaxel 200mgm
 2 over
24h alone. The results showed no significant difference in overall
survival among treatment arms, although cisplatin alone or in
combination yielded significantly higher tumour response rates
than paclitaxel monotherapy. It should be noted, however, that
early treatment crossover between groups was frequent in this
trial, and that paclitaxel therapy was frequently initiated after
cisplatin-only therapy. This use of nonprotocol therapy was
attributable principally to the presence of persistent disease as
determined either clinically or by reassessment surgery. The
similarity of results from the initial cisplatin (and crossover
paclitaxel) and combination arms suggests that sequential therapy
may be an effective approach. However, the trial was not designed
to determine the effect of sequential therapy and further study is
therefore needed to clarify this issue.
Feasibility trials for sequential therapy in ovarian cancer are
currently underway in Europe and the US. The Scottish Gynae-
cologic Cancer Trial Group SCOTROC-2 study programme is
currently recruiting patients in the UK and Europe (Kaye, 2001).
This series of trials is designed to assess four cycles of single-agent
carboplatin followed by a combination of docetaxel (or paclitaxel)
with CPT-11 or gemcitabine as first-line therapy in patients with
advanced ovarian cancer. First results of SCOTROC 2A, in which
gemcitabine was the agent being evaluated, have demonstrated that
this approach is feasible and highly active (Rustin et al, 2002;
Vasey et al, 2003). In an ongoing, randomised, German Arbeits-
gemeinschaft Gynaekologische Onkologie (AGO) trial, patients
receive paclitaxel–carboplatin chemotherapy followed by sequen-
tial topotecan. A feasibility trial for this approach was successfully
completed (Sadoze et al, 1999), and the results from the
randomised study were presented at ASCO 2003 (Pfisterer et al,
2003). Although feasible with regard to deliverability and toxicity,
early data do not demonstrate an improvement in PFS for this
approach. However, the primary end point of the study was overall
survival, and further follow-up is still required. Finally, another
alternative is to utilise the administration of sequential or
alternating doublets for as many as eight cycles of treatment —
this potentially retains the concept of preventing drug resistance
while introducing new agents in a less toxic way. A five-arm,
prospective, randomised trial is in progress by the Southwest
Oncology Group (SWOG), the Gynecologic Oncology Group
(GOG), the European Organisation for Research and Treatment
of Cancer (EORTC), the Medical Research Council (MRC) and the
National Cancer Institute of Canada (NCIC), with an accrual goal
of approximately 5000 patients. This study — GOG 182 (ICON 5 in
Europe) — is comparing four cycles of gemcitabine–carboplatin
followed by four cycles of paclitaxel–carboplatin vs four cycles
of liposomal doxorubicin/paclitaxel–carboplatin followed by four
cycles of paclitaxel–carboplatin vs four cycles of topotecan–
carboplatin followed by four cycles of paclitaxel–carboplatin vs
eight cycles of gemcitabine–paclitaxel–carboplatin vs eight cycles
of paclitaxel–carboplatin (control arm).
Dose-intense chemotherapy
Increased exposure to cytotoxic drugs has been used as a means of
circumventing drug resistance and potentially increasing the
response rates and survival times. A variety of randomised clinical
trials have been carried out to assess dose intensification of
platinum therapy, two of which showed a significant improvement
in survival with high-dose treatment (see review by Vasey and
Kaye, 1997).
The earliest of these studies (Ngan et al, 1989) was carried out in
50 assessable patients with debulked advanced epithelial ovarian
cancer, and showed 3-year actuarial survival rates of 60 and 30%
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 2) and low-dose (60mgm
 2) cisplatin,
respectively (both given every 3–4 weeks in combination with
cyclophosphamide 600mgm
 2). Notwithstanding this impressive
difference between groups, some doubt has been attached to the
results of this study because of the small size of the patient cohort
studied and because baseline disease characteristics were not fully
characterised. A later and larger study carried out by the Scottish
Gynaecologic Cancer Trials Group (159 patients) compared
cisplatin 50 with 100mgm
 2, with either dose given every 3 weeks
with cyclophosphamide 750mgm
 2, and showed respective
overall survival rates of 32.4 and 26.6% (overall relative death
rate¼0.68; P¼0.043) over 4 years after the start of the trial (Kaye
et al, 1996).
These results — while interesting — should be viewed in light of
other studies that have shown no significant difference between
high- and low-dose approaches (Vasey and Kaye, 1997). However,
many of these studies only aim to deliver up to two-fold increases
in platinum dose intensity; higher doses are not achievable in the
clinical setting without bone marrow or stem cell support. In
addition, substantial toxicity — particularly bone marrow and
neurotoxicities — was evident with the higher-dose cisplatin
treatment in both the above trials; to date, no large randomised
studies evaluating a role for true high-dose chemotherapy have
been performed. The conclusions from these data are that
increasing dose intensity two-fold has no impact on outcome,
and high-dose approaches are currently investigational and should
be reserved for properly designed clinical trials.
Intraperitoneal therapy
For over 20 years, investigators have explored the role of
chemotherapy administered directly into the peritoneal cavity for
patients with ovarian cancer (Jones et al, 1978). In principle, the
strategy allows tumour cells to be exposed to higher doses of
chemotherapy than would otherwise be possible with systemic
therapy. Ovarian cancer remains confined to the peritoneal cavity
for much of its natural history, making the disease an ideal
candidate for such a drug delivery strategy. The first randomised
trial exploring i.p. therapy as part of primary treatment in ovarian
cancer incorporated intravenous (i.v.) cyclophosphamide
(600mgm
 2) and i.v. or i.p. cisplatin (both at a dose of
100mgm
 2)i n4600 women with stage III ovarian cancer
(Alberts et al, 1996). A significant survival advantage in patients
treated with i.p. cisplatin compared with those in the i.v. cisplatin
arm was observed (49 vs 41 months, respectively; P¼0.02). There
was significantly reduced neutropenia and tinnitus, and an
expected increase in abdominal comfort observed in the i.p. arm.
There are, nevertheless, problems with the correct interpretation of
this study. Accrual was extended to include more patients with
residuum p0.5cm, the investigators rationalising that this group
would benefit most from i.p. chemotherapy. Counterintuitively,
there turned out to be no statistically significant survival benefit
for this group. In addition, as the i.v. cisplatin–cytoxan
combination has been shown to be inferior to cisplatin–paclitaxel
in two randomised studies, it is therefore not considered to be an
appropriate control arm with which to gauge any new therapy.
A subsequent randomised Phase III study has incorporated a
taxane into the treatment regimen (Markman et al, 2001). The
experimental arm comprised i.p. cisplatin (100mgm
 2) and i.v.
paclitaxel (135mgm
 2), while the control arm consisted of i.v.
cisplatin (75mgm
 2) and i.v. paclitaxel (135mgm
 2). The
experimental treatment was associated with a statistically sig-
nificant improvement in PFS (28 vs 22 months; P¼0.01), but there
was no significant improvement in overall survival. This trial
suffers from a number of design flaws, not least of which is the
fact that delivering two cycles of carboplatin at AUC 9 in addition
to six cycles of cisplatin–paclitaxel adds a longer duration of
chemotherapy and an increased cumulative dose of platinum, thus
unbalancing the trial in favour of the research arm, irrespective of
the mode of administration. In addition, the timing of salvage
therapies is not known, and may have influenced the PFS end point
if administered before progression (salvage therapies are also
likely to have influenced the overall survival, and were not
controlled). Furthermore, considerably greater toxicity was
observed in the experimental i.p. arm (grade IV thrombocytopenia
and grade III gastrointestinal).
Finally, the preliminary results of GOG trial 172 were presented
at ASCO in 2002 (Armstrong et al, 2002). This study randomised
417 patients cytoreduced to p1cm residuum to receive either six
cycles of i.v. cisplatin plus i.v. paclitaxel or six cycles of a 3-weekly
regimen consisting of i.v. paclitaxel (day 1), i.p. paclitaxel (day 2)
and i.p. paclitaxel (day 8). PFS was significantly longer in the i.p.
arm (24 vs 19 months, P¼0.029), although again there was
significantly greater grade 3–4 toxicity — especially metabolic,
neurological and gastrointestinal events and infections.
These results from three relatively large-scale clinical trials
carried out to date are all therefore positive for the i.p. approach
and — despite the criticisms outlined here — there may be an
emerging benefit accruing from this approach. As opined in a
recent editorial in the Journal of Clinical Oncology, ‘it is difficult to
think of any other setting in oncology where the results of three
positive trials have not led to widespread adoption of the superior
therapy’ (Alberts et al, 2002). The prevailing belief against i.p.
therapy may need to be overcome — and a less toxic regimen for
i.p. chemotherapy designed — before this treatment becomes part
of routine clinical practice.
DRUGS IN THE PIPELINE
As shown in Table 2, there are numerous novel agents in
development for the treatment of ovarian cancer, including those
designed to circumvent drug resistance mechanisms, signal
transduction inhibitors and angiogenesis inhibitors. Of particular
interest are the EGFR tyrosine kinase inhibitors. A number of
tumour types, including epithelial ovarian cancer, have a strong
association between levels of EGFR and decreased survival
(Nicholson et al, 2001). Aberrant EGFR activation is an important
factor in tumorigenesis and an essential driving force for
aggressive growth behaviour (Herbst and Shin, 2002). The binding
of growth factors (e.g. EGF) activates cell surface receptors,
which causes dimerisation (there are coreceptors, for example,
HER2/neu). Subsequent receptor autophosphorylation on tyrosine
residues occurs and these serve as docking sites for a number
of signal transducers and adaptor molecules. The end result is a
reaction cascade that leads to changes in proliferation, adhesion —
which are responsible for uncontrolled cellular growth — and
enhanced neovascularisation. Tyrosine kinase inhibitors such as
OSI 774 (Tarceva
s) are small molecules that compete internally
for the ATP-binding pocket catalytic domain of the receptor
tyrosine kinase. These and other agents in this class can be shown
Table 2 Novel anticancer agents in development
Drug class Agent
Signal transduction inhibitors Monoclonal antibodies (e.g. anti-Her2/neu
[trastuzumab])
EGFR tyrosine kinase inhibitors (e.g. ZD1839,
OSI 774)
Angiogenesis inhibitors VEGFR tyrosine kinase inhibitors (e.g. SU6668)
Thalidomide
Genetic therapy Circumvention of p53 resistance (e.g. ADP53,
ONYX-015)
E1A gene lipid complex
EGFR¼epidermal growth factor receptor; VEGFR¼vascular endothelial growth
factor receptor.
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et al, 2001) and may have synergism with platinum and taxanes.
Future trial designs utilising these and other novel biologic agents
will need to be careful to exploit their potential fully.
CONCLUSIONS
Further advances in the treatment of women suffering from ovarian
cancer will likely result from an improved understanding of clinical
drug resistance, optimal use of existing drugs (in particular, the
platinums and the taxanes) in new regimens (including possible
developments in sequential or i.p. chemotherapy) and the
integration of novel agents into current combinations. Multidrug
resistance proteins, MMR processes and alterations in the p53
pathway are examples of properties within tumour cells that may
lead to drug resistance. Novel agents designed to circumvent these
mechanisms (valspodar, ONYX-015 and ADP53) are currently
being investigated for ovarian cancer patients.
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